Literature DB >> 17437659

Novel paradigm for treating vasculopathy in systemic sclerosis: vascular progenitor cells and statins.

Monique Hinchcliff1, John Varga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17437659     DOI： 10.1007/s11926-007-0014-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  12 in total

1.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells.

Authors:  J Llevadot; S Murasawa; Y Kureishi; S Uchida; H Masuda; A Kawamoto; K Walsh; J M Isner; T Asahara
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

Review 3.  Endothelial progenitor cells for vasculogenesis.

Authors:  Satoshi Murasawa; Takayuki Asahara
Journal:  Physiology (Bethesda)       Date:  2005-02

4.  Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?

Authors:  Michael Simons
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

5.  Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells?

Authors:  Robert M Clancy
Journal:  Arthritis Rheum       Date:  2006-06

6.  Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.

Authors:  S Furukawa; S Yasuda; O Amengual; T Horita; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

7.  Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.

Authors:  Masataka Kuwana; Junichi Kaburaki; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Arthritis Rheum       Date:  2006-06

Review 8.  Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?

Authors:  Chris T Derk; Sergio A Jimenez
Journal:  Autoimmun Rev       Date:  2005-08-19       Impact factor: 9.754

Review 9.  Scleroderma: from cell and molecular mechanisms to disease models.

Authors:  David J Abraham; John Varga
Journal:  Trends Immunol       Date:  2005-09-15       Impact factor: 16.687

10.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.

Authors:  Oliver Distler; Angela Del Rosso; Roberto Giacomelli; Paola Cipriani; Maria L Conforti; Serena Guiducci; Renate E Gay; Beat A Michel; Pius Brühlmann; Ulf Müller-Ladner; Steffen Gay; Marco Matucci-Cerinic
Journal:  Arthritis Res       Date:  2002-08-30
View more
  1 in total

Review 1.  Circulating progenitor cells and scleroderma.

Authors:  Richard H Gomer
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.